SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-285489
Filing Date
2021-09-28
Accepted
2021-09-28 16:05:57
Documents
12
Period of Report
2021-09-22
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d398423d8k.htm   iXBRL 8-K 23631
  Complete submission text file 0001193125-21-285489.txt   141494

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA akba-20210922.xsd EX-101.SCH 2873
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20210922_lab.xml EX-101.LAB 17373
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20210922_pre.xml EX-101.PRE 10940
5 EXTRACTED XBRL INSTANCE DOCUMENT d398423d8k_htm.xml XML 3236
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 211286864
SIC: 2834 Pharmaceutical Preparations